Tetragon Financial Group — Offering a diverse exposure to alternative assets

Tetragon Financial Group (LSE: TFG)

Last close As at 21/12/2024

USD12.70

0.00 (0.00%)

Market capitalisation

USD1,775m

DISCLAIMER

Please read the Terms of Use below carefully.

You must accept these terms before you can proceed to content on Tetragon Financial Group.

Restrictions on Ownership by US Persons

Tetragon’s shares have not been and will not be registered under the United States Securities Act of 1933. Consequently, Tetragon shares may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, ‘US persons’ as defined in Regulation S under the Securities Act absent registration or an exemption from registration under the Securities Act. No public offering of any Tetragon shares is being, or has been, made in the United States.

In addition, Tetragon has not been and will not be registered under the United States Investment Company Act of 1940. Direct or indirect beneficial ownership of securities issued by Tetragon to any US person who is not a ‘qualified purchaser’ as defined in the Investment Company Act and applicable rules thereunder is prohibited. Under Tetragon’s Articles of Incorporation, the directors of Tetragon may in certain circumstances compel the transfer of any Tetragon shares owned directly or beneficially by any person who is not a ‘qualified purchaser’.

Ownership by Persons in Europe

Tetragon’s non-voting shares are not intended for European retail investors. Tetragon anticipates that its typical investors will be institutional and professional investors who wish to invest for the long term and who have experience in investing in financial markets and collective investment

undertakings and are capable themselves of evaluating the merits and risks of Tetragon shares and who have sufficient resources both to invest in potentially illiquid securities and to be able to bear any losses (which may equal the whole amount invested) that may result from the investment.

More on Tetragon Financial Group

View All

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

Pacla Medical — Backhug: Treating spinal joint stiffness

Pacla Medical is a private health care technology firm that has developed Backhug, a robotic physiotherapy device for treating pain. Pacla operates a scalable subscription model where customers typically pay £99/month for a 12-month contract (there is also a purchase option), potentially generating high levels of SaaS-type recurring revenue. The addressable market to reduce back pain is estimated at about 197 million people globally and worth $76bn in annual revenues. Pacla’s sales for the last 12 months were £21k; it has already sold 25 units and has a waiting list for 300. The planned £5m capital raise would allow expansion into the key US market and facilitate targeted growth to c 5k units over the next 18 months, with Pacla expecting FY24 sales to reach £14.1m.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free